Report of Foreign Issuer (6-k)
February 15 2018 - 1:51PM
Edgar (US Regulatory)
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For
period ending
15 February
2018
GlaxoSmithKline plc
(Name
of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or
will
file annual reports under cover Form 20-F or Form 40-F
Form
20-F x Form 40-F
--
Indicate
by check mark whether the registrant by furnishing the
information
contained in this Form is also thereby furnishing the
information
to the Commission pursuant to Rule 12g3-2(b) under the
Securities
Exchange Act of 1934.
Yes
No x
GlaxoSmithKline
plc (the
'
Company
')
2018 Award under the Deferred Investment Award
Programme
Notional Award
On 14
February, 2018 the Company granted an award over notional Ordinary
Shares to a Person Discharging Managerial Responsibilities ('PDMR')
under the GlaxoSmithKline Deferred Investment Award
programme.
The
PDMR joined the Company in September 2017 and the award is made
under the terms of the employment offer. The award will vest
25% on each of 4 September, 2020, 4 September, 2021, 4 September,
2022, and 4 September, 2023.
Under
the programme, awards are made over notional Ordinary Shares with
vesting phased over a specified period to provide long-term
alignment with shareholders. Vesting is subject to the PDMR
not having served the Company notice or having been terminated by
the Company for cause. Notional dividends will accrue on the
award during the vesting period through dividend reinvestment in
additional notional shares. On vesting, the award and accrued
dividends will be paid in cash. Executive Directors are not
eligible to receive awards under the
programme.
Transaction notification
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mr L Miels
|
b)
|
Position/status
|
President, Global Pharmaceuticals
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of
the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature of
the
transaction
|
A restricted award of notional Ordinary Shares under the Company's
Deferred Investment Award programme.
|
c)
|
Price(s)
and
volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£15.00
|
90,266.667
|
|
|
|
|
|
d)
|
Aggregated
information
|
n/a (single transaction)
|
Aggregated
volume Price
|
|
e)
|
Date
of the transaction
|
2018-02-14
|
f)
|
Place
of the transaction
|
n/a
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: February
15, 2018
|
|
|
|
|
By: VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|
GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024